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1. INTRODUCTION 
The integrity of all organisms to injury is conserved through intricate mechanisms of 
response, but none more so than the immune system of the mammals. The complexity 
and potency of these mechanisms make them both difficult and intriguing to dissect, 
but more importantly, the study of the immune system can be of benefit both 
therapeutically and diagnostically in a range of human diseases. While much have 
been learnt by studying how the immune system works in both immune and non-
immune diseases in humans and animals, the study of human immunodeficiencies 
gives an unique opportunity to study the consequences of an immune system inept to 
work. In this thesis I will present the work done by my colleagues and myself on 
innate, inflammatory and regulatory immune mechanisms in Common variable 
immunodeficiency (CVID), an immunodeficiency named more in keeping with the 
usual definition of “variable” than “common”, but with manifestations highlighting 
important principles of our current understanding of the immune system. In this 
introduction I will first briefly outline the normal human immune response before 
exploring parts of particular interest to my thesis. Thereafter, I will give a brief 
overview over human immunodeficiencies before examining the particular features of 
CVID in depth.  
 
1.1 THE IMMUNE RESPONSE 
The definition of the immune response requires some consideration as it has evolved 
in later years. While a broad definition includes the reaction of the body to any 
substance foreign or interpreted as foreign (1), the most common understanding is a 
response involving both specific and unspecific responses by leukocytes and proteins 
(2). Some, however, prefer a more strict and traditional definition including only 
reactions depending on specific reactions to antigens and the development of 
immunological memory (3). The growing evidence of close cooperation of all cellular 
components involved in the reaction to foreign substances would support a broad 
definition. Furthermore, while immunology traditionally has dealt with the response 
to infectious agents like bacteria, virus and parasites, it is clear that many of the same 
responses also apply to the human body’s reaction to toxins, malignant cells and even 
innocuous self-antigens causing auto-immune disease (4). Here however, I will sketch  
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Figure 1. Simplistic view of the immune response to a skin infection. 1. A pathogen will 
need to break the skin barrier before establishing a focus for infection. Tissue-resident macrophages 
(M) recognize the intrusion and start the inflammatory response, including recruitment of polymorpho-
nuclear neutrophil granulocytes (PMN). If this initial response is unable to clear the pathogen tissue-
resident dendritic cells (DC) will carry antigens from the invading pathogen to the nearest lymph node. 
2. In the lymph node, dendritic cells will activate helper T-cells (T ), cytotoxic T-cells (TH C) and 
possibly regulatory T-cells (TR) to activate and modify the adaptive immune response. Some TH-cells 
will activate and mature B-cells in the lymph node, leading to the massive production of 
immunoglobulins (Ig). 3. T - and TH C-cells will migrate to the inflammatory focus to help combat the 
pathogen, as will the circulation of specific immunoglobulins. The nature of this immune response will 
be modified according to the features of the invading pathogen.    
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out the immune response by example of the response to an invasion of a pathogen to 
the skin (Figure 1).  
The introduction of the pathogen to the human body relies firstly on the 
penetration of one of our main barriers to infection, the skin. This penetration is often, 
if not always, facilitated by the disruption of the skin barrier through a cut or other 
injury. When pathogens like e.g. bacteria have crossed this epithelial barrier they will 
localize and grow in the tissue close to the penetrating site causing inflammation. 
Local anti-infectious agents like peptides, proteins, plasma proteins, macrophages and 
granulocytes will then try to destroy and contain bacterial growth through the so-
called innate mechanisms of immune defense. The innate immune response is so 
tightly inter-woven with the process of inflammation that some authors even claim it 
is a misnomer; the innate immune response cannot be separated from acute 
inflammation and thus merits no separate name. Semantics aside, these innate 
immune mechanisms are conserved through evolution with remarkable penetrance in 
a wide range of organisms, and represent congenital and stable responses to foreign 
substances. The so called natural killer (NK) cells are also considered a part of this 
innate immune response. The amplification and coordination of this, as well as most 
other cellular responses in the immune system, relies on the secretion and recognition 
of cell signaling substances called cytokines between the participating cells. In this 
first encounter macrophages will secrete TNF-, IL-1 and IL-6 among other 
mediators of inflammation (such as prostaglandins and leukotrienes). While resident 
macrophages will encounter the pathogen first, the immediate response is more 
dependent on the migration of granulocytes to the site of inflammation by way of 
chemotaxis; a process of cellular movement towards a gradient of cytokines with a 
particular propensity for migration, the chemokines (e.g. IL-8 and MCP-1). This local 
response will furthermore facilitate the uptake of antigen, constituents from the 
invading pathogen able to elicit an immune response, by dendritic cells which will 
migrate to the closest lymph-node to present these antigens to T lymphocytes. This 
presentation marks the activation of the adaptive immune system. 
In contrast to the well preserved and stable genetic codes at the base of innate 
immunity, adaptive immunity is based on the ability of lymphocytes to recombine 
their genetic material to adapt to challenge by foreign subjects. The T lymphocytes 
will, depending on the way in which these antigens are presented, respond by clonal 
expansion and differentiation of T- and B cells, leading to tender and swollen lymph 
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+nodes. T cells are conventionally divided into the cytotoxic CD8  cells and the CD4+ 
helper T cells, TH1 and TH2 cells. While the CD8+ T cells are capable of eliminating 
cells infected with intracellular pathogens like virus, the CD4+ cells have a more 
complex role orchestrating the immune response by way of regulating and activating 
other immune cells. Most TH1 effector cells migrate to the focus of infection to help 
activate yet more macrophages through secretion of IFN-, IL-2 and TNF-. In 
contrast, the TH2 cells migrate within the lymph node to activate B cells by cell-to-
cell contact and secretion of IL-4, IL-5 and IL-6. When B cells are activated, they will 
mature into plasma cells, producing vast amounts of antibodies capable of targeting 
pathogen antigens for destruction by macrophages, complement proteins and 
granulocytes. The combined and coordinated response of all constituents of the 
immune system represents a powerful and usually devastating response to any 
pathogen trying to invade the organism. This impressive tour de force, however, 
comes with a price; collateral damage of cells and tissues may emerge if this process 
of innate and adaptive immune responses is without strict regulation. This regulation 
is facilitated by several factors, including the activation of the so-called regulatory T-
cells (T ).   Reg
Lymph nodes are stationed at strategically important sites surveilling 
incoming lymph from e.g. the limbs. If an infection is not contained in the local tissue 
or controlled by the local lymph nodes, pathogens may spread through the blood, 
creating other sites of infection or directly infecting the blood causing sepsis. The 
lymphoid organ responsible for the surveillance of circulating blood is the spleen, 
containing white pulp that has many overlapping functions with regular lymph nodes. 
Spleen and lymph nodes are collectively called secondary lymphoid organs in contrast 
to the primary lymphoid organs of bone marrow and thymus with an active role in the 
development of lymphoid cells.  
Infections manifesting themselves as disease and combated through the 
adaptive immune system likely represent a small fraction of the breaches of integrity 
due to infectious organisms but contained through innate mechanisms of immune 
defense. If the innate response fails to contain the pathogen, the level of pathogens 
will rise to a threshold where the innate response activates the adaptive response and 
both parts of the immune system act in concert to eliminate the pathogen (Figure 2). 
Notably, while symptoms of disease in infected tissues correlate with the level of 
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pathogens, symptoms are often more dependent on the immune response to the 
pathogen than on the pathogen itself.  
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Figure 2. Theoretical model of contribution of the innate and adaptive responses during 
an infection with a pathogen. The innate response (whole line) is the initial response to the pathogen 
and will in most cases contain and destroy the pathogen. If the pathogens succeed in reaching a 
considerable number, they will pass a certain threshold where the innate response activates the adaptive 
response (dotted line) and both parts of the immune system act in concert to eliminate the pathogen. 
Most pathogens will be eliminated asymptomatically by the immune system and not cause overt 
disease. 
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1.1.1 Inflammation 
Inflammation is primarily a protective response to cellular injury, from various trauma 
to infection, and is a basic and underlying process to the immune response, with the 
aim of restoring homeostasis to the affected tissues. Any inflammatory response can 
be seen to follow a pathway consisting of inducers, sensors, mediators and effectors. 
The different inducers will be recognized by more or less specific sensors leading to 
the release of mediators activating effectors, e.g. pathogens will be recognized by 
receptors leading to the release of cytokines activating effector cells. Inflammation 
has traditionally been defined as either acute or chronic and the definition of these 
merits some comments. The acute inflammation lasts from minutes to days, involve 
local tissue and innate mechanisms of immunity, including granulocytes. Chronic 
inflammation, on the other hand, is a process involving adaptive mechanisms of 
immunity, typically including lymphocytes and macrophages, and lasting days to 
years. Histologically, acute inflammation is characterized by the presence of an 
inflammatory exudate containing edema and a predominantly neutrophil infiltrate (2). 
Chronic inflammation, on the other hand, is characterized by infiltration of 
mononuclear cells (macrophages, lymphocytes), tissue destruction and repair 
(angiogenesis, fibrosis)(2). Biochemically, acute inflammation is characterized by the 
acute phase response involving high levels of local and systemic mediators like 
cytokines while these typically are more modestly expressed in chronic inflammation.  
The process of acute inflammation, with some important exceptions like 
allergic anaphylactic reactions, is generally considered a beneficial response for 
restoring tissue integrity. Chronic inflammation has a more ambiguous role; while it is 
an appropriate response leading to clearing of many important pathogens and 
resolution of the inflammatory state it may also be inappropriate leading to tissue 
damage with no apparent benefit to the host. This inappropriate activation is 
characterized by either a sustained response to an already cleared or contained 
pathogen, an erroneous response towards an innocuous antigen or a response towards 
self-antigens as seen in autoimmunity. Furthermore, while localized chronic 
inflammation has a clear role in diseases like tuberculosis, rheumatoid arthritis and 
silicosis mounting evidence also suggests a role for systemic chronic inflammation 
with largely negative effects in diseases like obesity and diabetes. These diseases are 
characterized by inflammatory traits albeit not of the nature usually seen in classic 
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inflammatory diseases. Thus, there is no focus of chronic inflammation and there is a 
low-grade response with low raise of systemic levels of inflammatory mediators. 
Recently, a state of para-inflammation was suggested as an intermediary step between 
tissues in a homeostatic equilibrium and the classic chronic inflammation, 
encompassing diseases where tissue malfunction, and not overt injury, would lead to 
(sub-)inflammatory responses (5).  
A central cell in the inflammatory response is the macrophage, acting as 
sensor, mediator and effector. Tissue-resident macrophages form a considerable part 
of most tissues and are known to have a central role surveilling peripheral tissues for 
possible intrusions like infection or trauma. However, they are also known to have a 
role controlling tissue homeostasis through phagocytosis of apoptotic cells and release 
of homeostatic mediators. The involvement of macrophages in inflammation can thus 
include both activation of the inflammatory response and adaption of tissue 
homeostasis to a new equilibrium. While macrophages in the basal state share many 
characteristics, activation of macrophages can lead to the development of functionally 
different classes of macrophages, recently described as classically activated, wound 
healing and regulatory macrophages(6). Common for all of these macrophages is the 
ability to respond to low intensity stimuli in the innate part of inflammation. The 
activation of macrophages is thus a sensitive marker of local tissue stress as seen in 
low-grade chronic inflammatory states(7).  
 
1.1.2 Innate immunity 
The development of multi-cellular organisms required potent mechanisms of defense 
against destruction, and mechanisms of host defense can be seen in lower organisms 
such as plants and non-vertebrates. Many of these phylogenetically old mechanisms 
are preserved in higher animals and humans, but some have possibly been rendered 
redundant by the evolution of an increasingly effective immune system.  This is, as I 
will discuss later, of particular interest in the study of deficiencies of this immune 
system.  
As previously mentioned, the innate mechanisms of immune defense are 
closely interconnected with inflammation and, one could argue, inseparable from it. 
However, some processes have by convention been associated more with the stricter 
term of innate immunity than the more widely defined term of inflammation.    
 15
At the basis of innate immunity is the presumption that there are some 
common and stable traits on the surface of pathological microbes like bacteria, virus 
and fungi. These traits or structures are called pathogen-associated molecular patterns, 
(PAMP). These molecular structures change only minimally over time and are thus 
possible targets for recognition by the immune system through the so called pathogen 
recognizing receptors (PRR). Both PAMPs and PRRs comprise a wide range of 
structures that likely will continue to be redefined and extended as we gather more 
knowledge of our immune system. Broadly speaking, innate mechanisms of immune 
defense will include anything from physical barriers of the human body towards the 
exterior, namely skin and mucosa, to NK-cells. I will here go into detail regarding 
some important parts of the innate immune system.   
Defensins and other anti-microbial peptides and proteins 
A primitive part of the immune system is the anti-microbial peptides and proteins 
constituvely found on epithelial surfaces or released from leukocytes upon activation.  
The defensins, -defensin and -defensin, are among the best described and are 
cationic peptides that are thought to destroy the bacterial cell wall. Lactoferrin and 
transcobalamin can bind iron and vitamin B12, respectively, vital nutrients to bacteria 
and thus inhibit bacterial growth. Another protein with recently described microbicid 
function is the urokinase plasminogen activator (uPA) that has been shown to act as a 
systemic endogenous antibiotic (8).      
 
The complement system and mannose-binding lectin 
The complement system, consisting of more than 30 proteins, represents an important 
component of the innate immune system. The hierarchical cascade of complement 
activation from any of three different starting points all lead to a final common 
pathway capable of neutralizing toxins, microbes and cells either directly through the 
membrane-attack complex or by opsonisation of pathogens (Figure 3).  Split products 
of this process, the so-called anaphylatoxins C3a, C4a and C5a, all act as mediators of 
inflammation contributing to the establishment of the inflammatory exudate, 
including recruitment of inflammatory cells. While the complement system plays a 
central role in the host defence against microbes, enhanced complement activation 
may also induce tissue damage and inflammation, through activation of both the 
terminal complex and the production of anaphylatoxins. Accordingly, a dysregulated  
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Figure 3. Overview of the complement system. The complement system can be activated through 
three different pathways all leading to recruitment of inflammatory cells, opsonization and killing of 
pathogens. Adapted from (4). 
 
 
complement system has been associated both with increased susceptibility to 
infections and autoimmune diseases (9;10).                                                                                                  
Mannose-binding lectin (MBL) is the key component of the lectin pathway of the 
complement system, binding to sugar residues on the surface of pathogens and 
marking them for destruction. Serum levels of MBL are closely correlated to 
polymorphisms in promotor regions as well as mutations in the MBL gene (11-
13).The extent of these malfunctions of the MBL gene is varying in different 
populations with high penetrance in tropic populations and lower penetrance in 
temperate and arctic populations. This has led to speculation that MBL deficiency 
may be of some value in tropic regions while a fully functioning MBL gene may be of 
benefit in more temperate regions. While any value of MBL deficiency is unclear, the 
benefit of MBL may be related to protection against particularly airway pathogens, 
which possibly is of importance in temperate and arctic regions. Some studies have 
found that children with recurrent sinopulmonary infections have low levels of MBL 
(14;15), but low MBL levels do not seem to increase mortality or the occurrence of 
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infectious disease in an adult population (16). On the other hand, altered MBL levels 
have been associated with persistent inflammation and tissue destruction, potentially 
contributing to the pathogenesis of some inflammatory disorders (17;18).  
 Toll- and other -like receptors 
The fruit-fly Drosophilia melanogaster has a receptor called Toll central in its defense 
against pathogens. In humans, receptors similar to Toll, the Toll-like receptors (TLR), 
are equally found to be immunologically active. As of today, 13 different receptors 
(TLR1-TLR13) have been identified, classified in 5 groups based on their structure. 
The receptors are expressed on a wide variety of cells from dendritic cells to B cells 
and respond to pathogens like Gram-negative bacteria (TLR4), Gram-positive bacteria 
(TLR2) and viruses (TLR3). TLR9 deserves special attention, it is together with 
TLR3, TLR7 and TLR8 located intracellularly. Furthermore, TLR9 is located in B 
cells and stimulated by CpG DNA, a DNA variant found in bacteria. The TLRs play a 
central part in the communication between the innate and the adaptive immune 
system, notably in the peripheral activation of dendritic cells and macrophages. The 
differential activation of TLRs as well as probable co-receptors  lead to secretion of 
both inflammatory and anti-inflammatory cytokines and can modulate the T-cell 
response in a TH1 or TH2 like manner (19). It is also suggested that TLR activation 
can lead to the production of anti-microbial peptides.   
 The discovery of intracellular TLRs has been followed by recognition of other 
innate intracellular receptors like the nod-like receptors (NLR). NLRs recognize 
bacterial constituents within the cell as well as other danger signals leading to 
activation of the cell.  
 
1.1.3 Adaptive immunity 
The presentation of antigens to lymphocytes marks the involvement of the adaptive 
immune system in the immune response. The ability of lymphocytes to recombine its 
genetic material to match an almost indefinite number of antigens is the primary force 
of this response. This adaption of the immune response leads to a specific attack on 
the antigen, and equally important, this adaption to the acute incident can be 
preserved throughout life with the development of immunological memory. Cellular 
immunity through the involvement of CD8+ T cells will not be commented upon here 
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as it is the humoral immunity based on the activation of CD4+ T cells and B cells that 
is the theme of this thesis.  
Antigen-presenting cells (APC) like dendritic cells present antigens to CD4+ T 
cells in the T-cell zones of the lymph node. The activation of these T cells requires a 
T-cell receptor with avidity for the presented antigen as well as co-stimuli in the form 
of binding to the CD28 and CD4/8 molecules on the T cells by the B7 (CD80 and 
CD86) and MHC II molecule on the APC, respectively. CD40L is also presented on 
the T-cell binding to the APC expressed CD40. Another important receptor for T-cell 
activation is CTLA-4 (CD152), a receptor resembling the B7 molecules but with 
higher avidity. Furthermore, the inducible co-stimulator (ICOS) is expressed on 
activated T cells and bind to its ligand (LICOS) present on dendritic cells, but 
importantly also on B cells which will be of interest to this discussion.  
The nature of T-cell activation will determine whether the CD4+ cells develop into 
TH1 or TH2 effector cells, and consequently deciding whether the response to the 
offending antigen will be cellular (T 1) or humoral (TH H2), profiled to combat either 
intracellular or extracellular pathogens, respectively. The mechanisms of this process 
are not fully known but some cytokines have an established role; the presence of IFN-
 and IL-12 will lead to a TH1 response, while IL-4 leads to a TH2 response. 
Furthermore, the phenotype of dendritic cells is known to be of importance as 
myeloid DC preferentially induce TH1 cells while the so-called plasma-cytoid DC 
have a propensity for T 2 cells.  While most activated TH H1 cells will migrate to 
peripheral tissues some will, together with the TH2 cells, remain in the lymph node to 
activate B cells. The activation of B cells requires recognition of the same antigen, but 
not exactly the same epitope, as that on the T-cell as well as contact between these 
cells. The binding of CD40L on the T-cell to CD40 on the B-cell is of importance, as 
well as T-cell production of IL-4, IL-5 and IL-6. Other signals include BLyS which 
binds TACI expressed by T cells. The initial contact and activation of B cells will be 
in the primary focus in the T-cell zone of the lymph node. Activation of B cells here 
will lead to the production of IgM but further activation will lead to migration into the 
B-cell zone of the lymph node called a primary lymphoid follicle. The presence and 
proliferation of activated B cells in this follicle will lead to the establishment of a 
germinal centre(7). In this germinal center, activated B cells with the continuing help 
of T cells, will refine the humoral response through isotype switching and somatic 
hypermutation.  
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The end product of the humoral defense system, the antibodies IgA, IgM, IgG and 
IgE is of particular interest in this thesis as it is the loss of one of them, namely IgG, 
that defines the disease at consideration and as the therapy available to these patients 
is the replenishment of the same antibody through intravenous infusion. Different 
types of antibodies have distinct localizations and functions. Antibodies have at least 
four major modes of function, all through their binding to antigens; 
 Neutralization through blocking of adhesive or toxic epitopes of the antigen 
(IgG, IgA) 
 Opsonization through binding to the surface of pathogens and subsequent 
binding of the antibodies to FC receptors on phagocytes (IgG) 
 Activation of complement through binding of antibodies to the C1 complex. 
This may lead to either activation of the complement cascade or to binding of 
the C1 complex to the complement receptor present on phagocytes and 
erythrocytes (IgM, IgG). 
 Sensitization of mast cells. Mast cells bind, in contrast to all other cells, 
unbound IgE antibodies through their FC receptors. The binding of the surface 
anchored antibody will then lead to activation of the mast-cell (IgE). 
The opsonizing function of IgG is particularly important in defense against 
polysaccharide capsuled bacteria as this capsule serves as a protection against non-
antibody mediated phagocytosis.  
 
1.1.4 Chemokines and chemotaxis  
Communication between cells not in contact depends on the cytokine network, a large 
group of soluble proteins active in a paracrine manner. Chemokines, chemotactic
cytokines, are a group of cytokines contributing to the migration of leukocytes 
between different cellular compartments like inflamed tissue, secondary lymphoid 
organs and the circulation (Table I). They act together with integrins capturing 
leukocytes in the circulation and leading them through the extra-cellular matrix. 
Functionally, chemokines have been divided between those associated with inflamed 
tissue, the inflammatory chemokines, and those seen in secondary lymphoid organs, 
the so called homeostatic chemokines. Not surprisingly, this dichotomy of 
nomenclature is challenged by ever increasing evidence of overlapping functions 
between chemokines. Structurally, chemokines have now been named and defined 
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based on the structure of a cysteine (C) motif in the N-terminal end of the amino acid 
sequence, and three major classes have been described; the CC, CXC and CXXXC (or 
CX3C) classes, where the X represents the presence of a non-cysteine amino acid 
(20). In all classes chemokines are named numerically, even if some names preceding 
this classification system are still in use. The chemokines act through activation of the 
chemokine receptors, a family of G-coupled receptors, named correspondingly to the 
chemokines as CCR, CXCR and CX3CR, respectively.  While some chemokine 
receptors like CCR2 are present on a wide variety of cells, others are presented more 
restrictively on subsets of leukocytes and have emerged as co-markers of certain 
subsets of leukocytes. A key feature of the chemokine network, however, is its 
redundancy with overlapping functions between chemokines and receptors. Notably, 
most receptors can be stimulated by more than one chemokine. 
 
 
Family Systematic name Original name Target cell Receptor 
5 RANTES Monocyte, 
macrophage, T-
cell, DC, NK cell 
CCR1, CCR3, 
CCR5 
CCL 
2 MCP-1 T-cell, monocyte, 
basophile 
CCR2 
19 MIP-3 Naïve T-cell, 
mature DC, B-
cell 
CCR7 
21 6Ckine Naïve T-cell, B-
cell 
CCR7 
CXCL 1 GRO- Neutrophil CXCR2, CXCR1 
 8 IL-8 Neutrophil, 
basophile, T-cells 
CXCR1, CXCR2 
 13 BLC/BCA-1 B-cell, activated 
CD4+ T-cell 
CXCR5 
CX3CL 1 Fractalkine T-cells, 
monocytes 
CX3CR1 
 
Table I. Selected chemokines. Chemotactic cytokines responsible for cytokine migration in both 
homeostasis and inflammation. Chemokines are now named and defined by the structure of a cysteine 
(C) motif in three classes; CCL, CXCL and CX3CL, as are their receptors; CCR, CXCR and CX3CR, 
respectively. The use of their original name is common (and sometimes confusing). DC = dendritic 
cell, NK cell = natural killer cell. 
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In addition to leukocytes, the most important cellular sources of chemokines 
are endothelial cells and various stromal cells, and there are also reports on 
chemokine receptors being expressed on cells other than leukocytes, like smooth 
muscle cells.  
Apart from propagation of migration, chemokines have stimulatory and 
regulatory effects on their target cells. This has important implications; first it 
establishes chemokines as central mediators of the immune response, secondly 
systemic levels of chemokines will not only be reflecting a local immune response in 
lymph nodes or peripheral tissue, they will directly affect the state of cells 
encountered in the circulatory compartment. Moreover, chemokines may affect non-
leukocytes cells like smooth muscle cells and endothelium. 
In the same way that chemokines have potential for more than inducing 
chemotaxis, proteins from other families can have chemoattractive properties. The 
urokinase plasminogen activator (uPA) is a member of the fibrinolytic system, but has 
together with its receptor uPAR been shown to promote chemotaxis of phagocytes 
and T cells. While regular chemokines stimulate chemotaxis through remodeling of 
the cytoskeleton, uPA exhibits an additional feature through the local proteolysis 
initiated by the binding of uPA to uPAR.  
 
1.1.5 Regulation of the immune response 
The appropriate responses of the immune system rest as much on tolerance of 
harmless antigens as on immunity against harmful antigens. This tolerance of 
harmless antigens is attributed primarily to the adaptive immune system and in 
particular the T cells. Central tolerance is mediated through mechanisms in primary 
lymphoid tissue and includes deletion of auto-reactive T cells. Peripheral tolerance 
includes anergy, suppression and immunological ignorance, and operates in secondary 
lymphoid tissue and peripheral tissues. These mechanisms of tolerance can be 
attributed to different steps in the immunological response and to different T-cell 
types. While e.g. anergy is dependent on the incomplete activation of effector T cells, 
suppression reflects activation of specific cells with a potential for what has lately 
been named regulation, rather than suppression.  
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Several cell types have regulatory properties, although some are poorly described; 
• Tr1; induced by antigen-stimulation, secretion of the modulatory cytokines IL-
10 and TGF-. 
• TH3; induced by oral antigens, secretion of TGF-. 
•  T cells; naturally occurring in mucosa, loss of these cells associated with 
autoimmunity.  
• NKT cells; surface markers for both for both T- and NK-cells. 
+• CD8  TReg ; uncertain identification. 
+CD25+ T• CD4 Reg ; naturally occurring regulatory T cells. 
+ + The identification and study of CD4 CD25 regulatory T-cells has been a 
breakthrough in our knowledge of peripheral tolerance. The removal of thymus from 
mice 3 days old was shown to lead to autoimmune disease while the simultaneous 
transplantation of CD4+ +CD25  cells alleviated this. Further examination of these cells 
found a subgroup expressing high levels of the IL2 receptor CD25 and the 
transcription factor FoxP3 with potent regulatory properties (21;22). These 
CD4+ High +CD25 FoxP3  cells have been called naturally occurring regulatory T 
cells(T ), as they, in contrast to e.g. Tr1 and TReg H3 cells, have suppressive properties 
independent of antigen stimulation. However, it seems clear that there also are 
inducible TReg expressing the FoxP3 factor, and as FoxP3 has also been found in 
CD8+ cells with a regulatory capacity, some claim that FoxP3 is a lineage marker for 
cells with regulatory functions. Interestingly, it has also been suggested that 
regulatory function is determined by higher-order processes that ensure the expression 
of FoxP3 (23). In any case, the importance of the identification of FoxP3 has been 
underscored by the fact that mutation of this transcription factor is associated with 
immune dysregulation and autoimmunity in both mice and man (24). Furthermore, 
while the co-expression of CD4 and CD25High previously has been used as a 
phenotype marker for TReg, the identification of FoxP3 now allows for a more strict 
and valid classification of T  even in clinical studies (25). Reg
The biological role of TReg is to suppress activity of primarily effector cells 
although it seems TReg are also capable of dampen responses in antigen-presenting 
cells like DC and B cells (26). The TReg use a variety of mechanisms to achieve this 
suppression, including killing of cytotoxic cells through cell-to-cell contact as well as 
secretion of anti-inflammatory cytokines like TGF- and IL-10 (27-29). The proper 
activation of T  will require signals from peripheral tissues, coordinating the Reg
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activation of TReg with the need for a down-regulation of the immune response, and 
are probably delivered through antigen-presenting cells like dendritic cells. 
  
1.1.6 Interaction and cooperation of innate and adaptive immune 
responses 
The traditional dichotomy of immune responses in either innate or adaptive is 
challenged by the increasing evidence of interaction that exists between the 
constituents of the immune system. It has long been known that innate responses are 
crucial for initiating adaptive immunity, and that the effector cells of the adaptive 
immune response uses innate mechanisms to amplify their response to the offending 
antigen. However, recent evidence suggests that innate immunity continues to modify 
the adaptive response also after antigens are presented and the adaptive cells are 
activated. Antiviral T cells will maximise their response if they are provided with 
innate stimuli also during the immune response, and the same signals will promote 
survival of effector cells (30). On the other hand, antigen-presenting cells are capable 
of down-regulating T-cell responses and proliferation, suggesting innate immune 
mechanisms are involved in regulating the contraction phase of the T-cell response 
(31).   
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1.2 PRIMARY IMMUNODEFICIENCIES 
 
The malfunction of one or more constituents of the innate or adaptive immune system 
may, despite the large degree of overlapping functions and redundancy of individual 
factors, lead to a clinical immunodeficiency. Importantly, immunodeficiencies can 
manifest themselves not only through increased susceptibility to infectious diseases 
but also through increased frequency of malignant disease and, more intriguingly, 
autoimmunity. Immunodeficiencies have traditionally been classified as either 
primary, due to an unknown cause or congenital genetic defect, or secondary, due to 
exposition to an immunosuppressive agent in the form infections, drugs, radiation or 
other. The advent of the HIV epidemic in the 1980’s suddenly made 
immunodeficiency a major contributor to human mortality and morbidity, and HIV 
and other secondary forms of immunodeficiencies, including iatrogenic variants, 
continue to rise in prevalence. However, there has also been a significant development 
in the smaller field of primary immunodeficiencies in later years, identifying yet more 
causes of immunodeficiencies and exploring them and previously described 
immunodeficiencies on the molecular level. The study of these syndromes may cast 
light also over more frequently occurring diseases. 
Primary immunodeficiencies can be caused by defects in both the innate and 
adaptive immune system, and so far over 150 different deficiencies have been 
described (32)(Table II). They span over a vast clinical spectrum with many of the 
most severe forms related to T-cell defects, while other forms seem to have little or no 
certain clinical consequence. Some primary immunodeficiencies exhibit a classic 
autosomal recessive or X-linked genetic inheritance, but in many forms the genetic 
cause is complex and probably also influenced by as of yet unknown environmental 
factors. Humoral immunodeficiencies, either through isolated B-cell defects or as a 
result of T-cell defects, constitute the majority of cases.  
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Localization of 
deficiency 
Subgroup Name Inheritance Clinical 
severity 
C2-deficiency Autosomal 
recessive 
++ Innate Complement 
MBL-deficiency Complex, 
autosomal 
recessive 
-(?) 
Phagocytes Chronic granulomatous 
disease 
Complex, X-
linked 
++ 
Severe combined 
immunodeficiency 
(SCID) 
Different 
genetic causes, 
most X-linked 
+++ Adaptive T-cells 
MHC I deficiency Autosomal 
recessive 
+ 
MHC II deficiency Autosomal 
recessive 
+++ 
IgA deficiency Autosomal 
recessive 
+ B-cells 
Hyper IgM syndrome Complex, most 
X-linked 
++ 
Brutons/X-linked 
agammaglobulinemia 
(XLA) 
X-linked ++ 
Common variable 
immunodeficiency 
Complex ++ 
 
Table II. Selection of primary immunodeficiencies. Immunodeficiencies can affect almost any 
constituent of the immune system, some are asymptomatic while others are severe and fatal. 
 
1.2.1 Common variable immunodeficiency 
Diagnosis
Hypogammaglobulinemia can occur secondary to other immunological or non-
immunological diseases but the hallmark of CVID is the absence of IgG-antibodies 
not related to any other known disease. The many causes of hypogammaglobulinemia 
makes the definition and diagnosis of CVID a matter of exclusion, and this is 
furthermore complicated by the heterogeneous nature of both clinical symptoms and 
etiology in CVID. The WHO expert group on primary immunodeficiencies, the IUIS 
(International Union of Immunological Societies) scientific committee, has defined 
the diagnosis of CVID as being defective antibody formation with decreased serum 
levels (>2 SD) of IgG, IgA and/or IgM, together with exclusion of other forms of 
hypogammaglobulinemia, most notably the Hyper IgM syndrome and Brutons 
agammaglobulinemia (X-linked agammaglobulinemia, XLA)(33). Others use a 
stricter definition, further requiring age at onset of symptoms to be over 2 years and 
poor antibody responses (i.e. absence of isohemagglutinins or poor response to 
vaccines)(34).  
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Epidemiology and etiology 
CVID is the most prevalent primary immunodeficiency with an estimated prevalence 
of 1:50 000 to 1:200 000 (32) and with an equal sex distribution. The disease usually 
manifests itself in the third decade although there is a wide range of age at debut 
(35;36), with diagnosis typically delayed by several years. CVID is associated with 
significantly increased mortality, even if survival data seem to be improving (36). No 
clear pattern of inheritance has been established in CVID and most cases seem to be 
of a sporadic nature, even if the disease has been seen to cluster in some families. In 
recent years, four genetic defects affecting co-stimulatory molecules in B and T cells 
(ICOS, CD19, BAFF-R, TACI) leading to CVID have been identified on a molecular 
level. These genetic defects only accounts for a fraction of all cases and each will be 
discussed in more detail later. However, it is noteworthy that all defects concern co-
stimulatory molecules illustrating the role of co-stimulation in the immune response. 
Other possible etiological agents include infections and certain medications although 
there is no proven association between these factors and CVID.  
Clinical features 
CVID patients can present a variety of symptoms from different organ systems 
(Figure 4). Recurrent sino-pulmonary infections are the most common clinical 
manifestation of CVID, affecting nearly all patients (35). These infections may be 
complicated by the development of chronic sinusitis, chronic otitis and bronchiectasis. 
Bronchiectasis represent the most common pulmonary complication, affecting >25% 
of patients, and it is associated with increased mortality (36). Common pathogens are 
encapsulated bacteria like H.influenzae and S. pneumoniae highlighting the 
importance of opsonizing by IgG in the defense against these bacteria. However, 
patients are also prone to infections with atypical bacteria like Mycoplasma spp (32). 
Gastrointestinal infections by Salmonella, Campylobacter and Giardia are over-
represented in the CVID population as well as enteroviral infections. The CVID 
population shares many of these pathogens with XLA patients pointing to the 
protective role for IgG in immune defense against them. In contrast, while CVID 
patients are prone to severe Herpes Zoster infection this is rarely seen in XLA, 
possibly reflecting the more profound immune deficiency seen in some CVID 
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patients. The aggressive course of Hepatitis C infection in CVID patients as compared 
to XLA further underscores this difference (37). 
Malignant diseases, both solid and non-solid tumors, affect a disproportionate 
part of the CVID population, most strikingly Non-Hodgkin lymphomas affecting 
approximately 3-7 % of patients but there is also an increased risk of gastric 
carcinomas (35;36). 
 
 
 
Figure 4. Organ systems involved in the pathogenesis of CVID. Left; healthy organs. Right; organ-
system involvement. By permission from (32).  
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CVID is characterized by a high frequency of autoimmune features, in 
particular idiopathic thrombocytopenia and autoimmune haemolytic anemia (6-7% 
and 4-5% of patients, respectively), which in some cases mark the debut of the disease 
(35;36). Other autoimmune features include pernicious anemia, atrophic gastritis, 
autoimmune thyroiditis and rheumatoid arthritis. Furthermore, villous atrophy and 
anti IgA antibodies is seen in a number of patients, and non-infectious chronic 
diarrhea is a common problem. 
Benign lymphoid hyperplasia is seen in many patients with splenomegaly 
being the far most common manifestation (30-40% of patients)(36;38;39). However, 
nodular intestinal lymphoid hyperplasia is also present. The etiology of lymphoid 
hyperplasia in CVID is unknown, and possible causes would include chronic infection 
with low-virulent pathogens. On the other hand, CVID patients have an increased risk 
of developing lymphomas and lymphoid hyperplasia could thus also be seen as a 
feature related to intrinsic lymphocyte defects. Furthermore, non-caseating 
granulomas are also seen in lungs, spleen and the gastrointestinal tract independently 
of lymphoid hyperplasia (32;40). These granulomas represent a probably under-
reported complication of CVID as it rarely gives symptoms and only can be 
diagnosed through biopsy of the affected organ. They are suggestive of a classic 
chronic infectious focus but no pathogen has so far been isolated, raising the 
possibility of an autoimmune focus. In any case, the granulomas could be seen as the 
result of failure of feedback mechanisms normally constraining lymphocyte 
proliferation. 
 The heterogeneous clinical picture of CVID reflects not only the various 
defects behind the hypogammaglobulinemia, but also the profound perturbation of the 
immune system some of these separate defects may lead to.     
Immunological features – general consideration 
The fact that many CVID patients have B cells with appropriate response to 
stimulation in vitro demonstrate that while the hypogammaglobulinemia per se affects 
the adaptive immune system, other defects in the closely interacting chain of events 
leading up to an appropriate antibody response may cause CVID (41). The search for 
these defects are complicated, not least due to the fact that any defect causing 
hypogammaglobulinemia as well as the hypogammaglobulinemia itself, can affect 
other parts of the immune system, making the distinction between primary and 
 29
secondary changes to the immune system in CVID difficult. However, in general, 
CVID is characterized by features of systemic inflammation, including raised 
circulatory levels of inflammatory cytokines and markers of oxidative stress (42-45). 
 
Features of innate immunology
The essential function of the innate immune response is to remove intruding agents 
and if this fails, to activate the adaptive immune response through presentation of 
antigens to T cells. In CVID, innate immunity may be of particular importance to 
clear as many pathogens as possible through responses independent of the adaptive 
immune system. Furthermore, the processing and presentation of antigens by the 
innate response affects both magnitude and specificity of the adaptive response. 
Dendritic cells are the most potent of antigen-presenting cells and both quantitative 
and qualitative abnormalities have been seen in CVID. CVID patients are 
characterized by low levels of dendritic cells, both within the myeloid and 
plasmacytoid subset (46-48), stimulating TH1 and TH2 responses, respectively. As 
mentioned earlier, activation of TH1 effector cells lead to a cellular immune response 
while a TH2 response would cause a predominantly humoral response. Thus, the 
antibody deficiency of CVID could stem from an imbalance in the regulation of these 
two responses. There are data supporting an upregulation of the TH1 response in 
CVID through increased serum levels of IL-12, as well as enhancement of the IL-
12/IFN- cytokine loop in monocytes and T cells (47;49;50). Dendritic cells from 
CVID patients however, produce low levels of IL-12 as compared to controls (51;52). 
Dendritic cells from CVID patients furthermore show immature characteristics with 
deficient presentation of receptors relevant for T-cell stimulation (51;53). 
Interestingly, impaired differentiation of dendritic cells in CVID has been associated 
with low levels of circulating antibodies (54).  
While there is no quantitative change of monocytes in CVID, patients have 
activated monocytes as reflected by increased serum levels of neopterin as well as 
enhanced generation of reactive oxygen species and spontaneous TNF- release 
(43;45;55). Interestingly, while these monocytes are activated in vivo their response to 
stimulation in vitro seem hampered, suggesting this inappropriate activation is 
combined with a failure of adequate response to stimuli (45).   
There are some studies of single complement components in CVID, but no 
systematic study of complement deficiency and CVD has been reported (56;57). This 
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paucity of studies also applies to other constituents of the innate immune system 
which represents novel and interesting approaches to a disease defined by failure of 
the adaptive immune response.    
 
Features of adaptive immunology  – T cells  
Various T-cell abnormalities in CVID have been reported for many years including 
low expression of the co-stimulatory molecule CD40 ligand which is essential for B-
cell activation. However, the discovery of ICOS-deficiency as a cause for CVID was 
a breakthrough (58). It established that T-cell defects could be a cause for CVID and 
it was the first genetic defect shown to cause CVID. ICOS is expressed mainly on 
activated T cells and is activated by ICOS-ligand expressed on B cells and antigen-
presenting cells releases. The activation of ICOS leads to the secretion of several 
important cytokines from the T-cell, but it seems to be pivotal for the secretion of IL-
10 and expression of CXCR5 (59). While the expression of CXCR5 is essential for 
the co-localization of B and T cells in the lymph node, IL-10 is needed for the 
terminal differentiation of B cells. Thus, ICOS deficiency attenuates the stimulatory 
interaction between otherwise normal B and T cells. ICOS-deficiency is an autosomal 
recessive genetic defect and so far nine patients have been described (32). The effects 
of the ICOS deficiency parallels that of the low expression of the co-stimulatory 
molecule CD40 ligand previously described in T cells from some CVID patients (60). 
Phenotypically, the T-cell population in CVID has a decreased CD4/CD8 
ratio, as well decreased proportions of CCR7+ + and CD45RA  T cells characterizing a 
shift from a naïve towards an inflammatory T-cell phenotype (61-66). Other features 
include attenuated proliferative response to mitogens in vitro, as well as increased 
proportions of apoptotic markers (35;67). T cells from CVID patients further fail to 
show antigenic specificity after vaccination (68). Thymic output of naïve lymphocytes 
is reduced while peripheral proliferation of both CD4+ + and CD8  T cells are increased 
(67;69).The cytokine profile in stimulated T cells from CVID patients reveal an 
increase in the levels of IFN- and a decrease in IL-10 (67;70), and growing insights 
into T-cell relevant cytokine networks makes this an interesting area of research. 
Furthermore, advances in the area of regulatory processes may be of potential 
relevance to T-cell mediated inflammation in CVID. 
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Features of adaptive immunology – B cells  
As noted, many CVID patients seem to have normal B-cell function in vitro, and only 
a minority of patients has B-cell lymphopenia. However, both phenotypic and 
functional abnormalities have been observed in the B-cell population of CVID 
patients, some being causative of the disease.  
While the B-cell lymphopenia in some patients suggests a defect in early B-
cell differentiation, other CVID patients are characterized by low numbers of 
CD27+IgD- switched memory B cells pointing to a defective terminal differentiation, 
possibly by failure of germinal centre development (39;71;72). TLR9 is an 
intracellular receptor that is a potent inducer of converting B cells to plasma cells. The 
ligation of CpG-DNA to TLR9 leads to proliferation and differentiation of B cells 
from healthy controls. In contrast, CVID patients show a quantitative and functional 
TLR9 defect not only in B cells but also in plasmacytoid dendritic cells (73).  
The identification of the T-cell associated ICOS-deficiency as causative to 
CVID has been followed by the identification of several B-cell associated genetic 
defects leading to CVID. CD19 is used as a marker of B cells and is, in complex with 
other proteins and the B-cell receptor, essential for B-cell activation. There are now 
three CD19 mutations identified (74;75). Mutations have also been found in the 
APRIL-BAFF network which is essential for B-cell development and survival 
(59;76). B-cell activating factor receptor (BAFF-R)(TNFRSF13C) is expressed on 
naïve circulating B cells while Transmembrane activator and calcium-modulating 
cyklophilin ligand interactor (TACI)(TNFRSF13B) is expressed in germinal center B 
cells. The TACI mutation is the most prevalent, possibly affecting up to 10% of 
patients, but there is no clear association to a particular clinical phenotype (77;78). 
The involvement of the APRIL-BAFF network in CVID is further suggested through 
enhanced levels of the ligands to BAFF-R and TACI, namely APRIL and BAFF (79). 
 
Classification
The heterogeneous nature of CVID has prompted several attempts to classify patients 
according to clinical or immunological criteria (36;39;41). The main challenge of 
classifying CVID is the relative weak association between immunological, clinical 
and genetic features, not least highlighted in the heterogeneous clinical picture of the 
CVID patients with the TACI-defect (78). As previously noted, some CVID patients 
are characterised by low numbers of isotype switched memory B-cells and in later 
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years several groups have proposed classifying patients according to this B-cell 
phenotype, most recently in the EUROCLASS trial (39). However, the clinical value 
of this classification is uncertain (36), and no consensus in classification of CVID has 
yet been reached. 
 In articles focusing on inflammatory characteristics in CVID we have 
previously described a subgroup of patients (CVIDHyper) with chronic inflammation in 
vivo as reflected by splenomegaly and increased serum levels of the monocyte 
activation marker neopterin (42;43;55). This subgroup of patients, in contrast to the 
other patients classified as CVIDNorm, shows a consistent pattern of raised 
inflammatory markers and allows for a relatively robust classification of CVID 
patients. 
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2. PURPOSE OF THE STUDY 
To explore the possible contribution of innate, inflammatory and regulatory immune 
mechanisms in the pathogenesis of CVID. 
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3. SUMMARY OF RESULTS 
 
3.1 PAPER I; COMMON VARIABLE IMMUNODEFICIENCY AND 
THE COMPLEMENT SYSTEM; LOW MANNOSE BINDING LECTIN 
LEVELS ARE ASSOCIATED WITH BRONCHIECTASIS 
 
The objective of this study was to evaluate mannose-binding lectin (MBL) and the 
complement system in relation to clinical and immunological parameters in patients 
with common variable immunodeficiency. Circulating levels of MBL, complement 
components, complement activation products and functional capacity of complement 
pathways were correlated to clinical features in CVID patients and compared with 
healthy controls.  The main findings were;  
 The patients had signs of increased complement activation significantly 
associated with signs of an inflammatory phenotype. 
 There was no evidence of deficiencies of the classical and alternative 
complement pathways in the patient group.  
 The prevalence of lectin pathway deficiency was the same in patients and 
controls, but patients with increased frequency of lower respiratory tract 
infections or bronchiectasis had lower capacity of the lectin pathway than 
patients without these features. 
 The serum concentration of MBL was inversely correlated with the frequency 
of lower respiratory tract infections and bronchiectasis.  
Conclusion; Patients with common variable immunodeficiency do not have increased 
frequency of complement deficiencies but signs of increased complement activation 
associated with an inflammatory phenotype. MBL and the lectin complement pathway 
may contribute to protection against lower respiratory tract infections in patients with 
common variable immunodeficiency. 
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3.2 PAPER II; ENHANCED LEVELS OF UROKINASE 
PLASMINOGEN ACTIVATOR AND ITS SOLUBLE RECEPTOR IN 
COMMON VARIABLE IMMUNODEFICIENCY 
 
The urokinase plasminogen activator (uPA), its cell bound and soluble receptor 
(uPAR, suPAR) have complex biological functions involving innate immune defense 
mechanisms and regulation of inflammation. Based on this dual role, we hypothesized 
that the uPA system could be affected in CVID, and examined expression of 
components of the uPA system in subgroups of CVID. Circulating levels of uPA and 
suPAR were correlated to clinical features in CVID patients and compared with 
healthy controls.  Monocytes from CVID patients were analysed for uPAR expression 
by means of flowcytometry. The main findings were: 
 All CVID-patients had increased plasma levels of suPAR with particularly 
high levels in those with splenomegaly and thrombocytopenia.  
 Plasma uPA levels were also raised in patients with splenomegaly and 
thrombocytopenia. 
 suPAR and uPA levels correlated with circulating levels of the monocyte 
activation marker neopterin.  
 Monocytes from CVID patients had increased expression of uPAR.  
Conclusion; We show an inappropriate activation of the uPA system possibly 
contributing to the inflammatory phenotype seen in subgroups of CVID patients. 
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3.3 PAPER III; CHEMOKINES AND COMMON VARIABLE 
IMMUNODEFICIENCY; POSSIBLE CONTRIBUTION OF THE 
FRACTALKINE SYSTEM (CX3CL1/CX3CR1) TO CHRONIC 
INFLAMMATION  
The chemokine fractalkine (CX3CL1) and its receptor CX3CR1 is suggested to play 
an important role in the pathogenesis of several inflammatory disorders. We 
hypothesized that enhanced CX3CL1/CX3CR1 interaction could be involved in the 
chronic inflammation characterising subgroups of CVID. Circulating levels of 
CX3CL1 were correlated to clinical features in CVID patients and compared with 
healthy controls.  T cells from CVID patients and controls were analysed for 
expression of CX3CR1 by means of real time RT-PCR and flowcytometry. Peripheral 
blood mononuclear cells from patients and controls were stimulated with CX3CL1. 
The main findings were: 
 CVID patients were characterized by raised plasma levels of CX3CLl and 
enhanced expression of its corresponding receptor CX3CR1 on CD4+ and 
CD8+ T cells, including both CD45RA+ and CD45RA- subsets.  
 CX3CR1 expression was particularly enhanced in patients characterized 
by chronic inflammation in vivo.  
 High expression of CX3CR1 in CVID patients was accompanied by 
enhanced chemotactic, adhesive, and other inflammatory cell responses to 
stimulation with CX3CL1.  
Conclusion; We demonstrate increased levels of CX3CL1 and CX3CR1 in CVID and 
suggest that increased CX3CL1/CX3CR1 interaction may contribute to the 
inflammatory phenotype seen in subgroups of CVID patients. 
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3.4 PAPER IV; CHEMOKINES AND COMMON VARIABLE 
IMMUNODEFICIENCY; POSSIBLE CONTRIBUTION OF CCL19, 
CCL21 AND CCR7 TO IMMUNE DYSREGULATION  
The homeostatic chemokines CCL19 and CCL21 and their corresponding receptor 
CCR7 have recently been associated with modulation of inflammatory and anti-
inflammatory responses. Previous reports have demonstrated decreased proportions of 
CCR7+ T-cells in CVID and in this study we investigated quantitative and functional 
aspects of CCL19, CCL21 and CCR7 in CVID patients. The main findings were: 
 CVID patients had raised serum levels of CCL19 and CCL21 independent of 
features of chronic inflammation.  
 CCL19 and CCR7 was similarly expressed in spleens from CVID patients and 
controls, while CCL21 was variably down-regulated in spleens from patients.  
 T-cell expression of CCR7 was particularly low in patients characterized by 
chronic inflammation.  
 PBMC from CVID patients had attenuated cytokine responses to stimulation 
with CCL19 and CCL21  
Conclusion; We demonstrate enhanced expression of CCL19 and CCL21, and an 
attenuated cytokine response to stimulation with these chemokines. CCR7, CCL19 
and CCL21 are key mediators balancing immunity and tolerance; abnormalities of 
these mediators might contribute to the profound immune dysregulation seen in 
CVID.  
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3.5 PAPER V; LOW NUMBERS OF REGULATORY T CELLS IN 
COMMON VARIABLE IMMUNODEFICIENCY; ASSOCIATION 
WITH CHRONIC INFLAMMATION IN VIVO 
Abnormalities of CD4+CD25High +FoxP3  regulatory T cells (TReg) have been associated 
with autoimmune and inflammatory disorders, and we hypothesized that CVID might 
be characterized by T  abnormalities. CD3+Reg  cells from patients and controls were 
analysed for the expression of FoxP3 mRNA by real time RT-PCR. Peripheral blood 
mononuclear cells from CVID patients and controls were stained for TReg markers, 
analysed by flow cytometry and compared to clinical characteristics. The main 
findings were;  
 CVID patients had significantly decreased expression of FoxP3 mRNA and 
decreased proportions of CD4+ High +CD25 FoxP3  cells compared to controls.  
 CVID patients with splenomegaly had lower proportions of TReg compared 
than other patients and controls. 
 Serum levels of the inflammatory marker neopterin were negatively correlated 
to the proportions of TReg within the CVID population, while there was no 
significant association with bronchiectasis.  
Conclusion; We demonstrate decreased proportions of TReg in CVID patients, 
particularly in those with signs of an inflammatory phenotype. Decreased proportions 
of TReg are suggested to be pathogenetically important in autoimmunity, and our 
results suggest that T  may have a similar role in CVID. Reg
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4. DISCUSSION 
 
4.1 METHODOLOGICAL CONSIDERATIONS 
 
Selection of patients 
The patients included in the studies of this thesis were recruited from  Section of 
Clinical Immunology and Infectious Diseases at Rikshospitalet University Hospital, 
Oslo, Norway. Informed consent to blood sampling was obtained from all subjects, 
and the project has been approved by the regional ethical committee. 
Patients included in the study were diagnosed with CVID according to the 
criteria of the World Health Organization expert group for primary 
immunodeficiencies, which includes patients with decreased serum levels of IgG, IgA 
and/or IgM, confirmed in repeated samples with no other specific cause of 
hypogammaglobulinemia (33). While patients furthermore had onset of symptoms 
after 2 years of age, in accordance with the stricter definition of CVID as 
recommended by ESID, data on antibody responses are incomplete. Similar modified 
criteria have also been used in two recent European studies (36;39) . The estimated 
onset of symptoms, especially the increased frequency of infections which is the main 
debut symptom, is often difficult to assess in retrospect. A more precise estimate is 
possible in the few patients presenting with ITP or hemolytic anemia. 
Patients with XLA, Hyper IgM-syndrome and X-linked lymphoproliferative 
disease were excluded based on current criteria (33). Our centre performs testing for 
the Btk-gene, which is mutated in XLA, in male patients with 
hypogammaglobulinemia based on clinical suspicion of XLA, i.e. low B-cell count 
and suspected debut of disease in early childhood.  
Interpretation of data from CVID patients merits a note of warning; “variable” 
is the key word to both clinical and scientific evaluation of these patients, and this 
means that observed differences between the CVID patients and healthy controls 
often relates to a subgroup of patients. We have performed B-cell phenotyping 
according to the EUROCLASS study on 20 patients for manuscript nos 3, 4 and 5 but 
found no certain association between B-cell phenotype and relevant markers in these 
studies (39). In manuscript 4 and 5 patients were classified as CVIDHyper if they had 
splenomegaly (>13 cm on ultrasonographic or CT scan examination) and serum 
neopterin levels greater than the mean + 4 SD of healthy controls (11.5 nmol/l). 
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Bronchiectasis were defined based on typical findings on high-resolution computed 
tomography of the thorax (80;81).The definition of autoimmune disease included 
idiopathic thrombocytopenic purpura, autoimmune thyroiditis, haemolytic anaemia 
and autoimmune colitis. 
  CVID patients are prone to bacterial infections and subsequent antibiotic 
treatment which may influence measurement of inflammatory markers. However, 
patients recruited had no clinically apparent infection at the time of sampling and did 
not receive acute or prophylactic treatment with antibiotics. The anti-inflammatory 
effect of IVIG is well known, and to minimize this effect in our studies, patients who 
received IVIG substitution, typically with an interval of 3-4 weeks, were sampled 
immediately before IVIG administration. Furthermore, data were compared between 
patients on IVIG and SCIG where concern was raised regarding the effect of IVIG. 
Auto-immune manifestations in CVID patients sometimes require treatment with anti-
inflammatory drugs, most notably corticosteroids. Patients recruited in our study did 
not receive corticosteroids or other anti-inflammatory treatment.  
Known genetic causes of CVID include mutations in ICOS, BAFF-R, CD19 
and TACI. While mutations of ICOS, BAFF-R and CD19 has been shown in 9, 1 and 
4 CVID patients, respectively, defects in TACI is more frequent and homo- or 
heterozygote mutations has been described in close to 60 patients so far (77). Our 
patients have not been tested for known genetic causes of CVID, but the relatively 
low frequency of mutations suggests any specific finding in our studies would lack 
statistic power to lead to any reasonable conclusions. 
 
Laboratory methods 
Laboratory methods and reagents used in this thesis are thoroughly described in 
papers I-V, and most will not be further discussed here. However, some of the 
methods merit general consideration. 
All laboratory methods used required blood sampling and preparation from 
patients and controls. Samples may be exposed to both ex vivo 
activation/apoptosis/necrosis of cells or degradation of proteins, even if standard 
laboratory procedures as described in the manuscripts are used. Importantly, samples 
from patients and controls were analyzed at the same laboratory by the same protocol, 
minimizing any systematic effect of such effects. For flowcytometry of cryopreserved 
cells, necrotic cells were excluded from analyses by propidium iodide staining.  
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Protein levels in serum, plasma and cell culture supernatants were analysed by 
commercially available enzyme-linked immunosorbent assays (ELISA). Although this 
is a well-proven and much used laboratory method it is worth noting that specificity 
of reagents varies between manufacturers and also in assays from the same 
manufacturer. Addressing this, all analyses of a specific protein were run on kits from 
the same manufacturer. Furthermore, samples for comparison, i.e. samples from 
patients and controls or samples from unstimulated and stimulated cell cultures, were 
run on the same microtiter plate. 
Expression of extra- and intracellular proteins were assessed by flow 
cytometry. This is in general a reliable and specific method for quantification of 
protein expression although it depends on the nature of the protein expression. 
Proteins expressed in a categorical manner, like the phenotypic markers CD4 and 
CD8, are generally easier to evaluate than proteins expressed in a continuous manner, 
like the activation marker CD25. The specificity of antibodies, which can vary 
between individuals and also between different subsets of cells in the same individual, 
is at the centre of this discussion. The use of unspecific antibodies of the same isotype 
as the specific antibody, the so called isotype controls, seeks to assess the degree of 
unspecific binding in each assay and has been used extensively in our studies here. 
Unspecific isotypes can either be used to establish a threshold for gating of 
specifically stained cells, or to calculate the mean fluorescence intensity (MFI) of a 
specific antibody in a cell population. While gating of positive cells is preferable with 
categorically expressed markers, the calculation of MFI is preferable with 
continuously expressed markers. In our studies, both methods were used as 
appropriate (e.g. gating of positive cells and calculation of MFI in fractalkine and 
suPAR manuscripts, respectively).   
In vitro cell cultures were used to study functional capacity of stimulation with 
specific proteins on cells from patients and controls. These functional responses were 
assessed by measurement of secreted cytokines in the supernatant. As for ELISA 
assays, samples for comparison were run on the same microtiter plate to minimize 
effect of inter-assay variation. Some proteins have weak stimulatory effect when 
given alone to cells in vitro, while interesting effects are revealed when the protein is 
given as an adjuvant to cells sub-optimally stimulated with other stimulants. Such co-
stimulatory conditions are clearly relevant of the in vivo situation where various cells 
are simultaneously exposed to a wide variety of stimulants. In our studies, we have 
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used the mitogen phytohemagglutinin (PHA) in sub-optimal doses as determined by 
preliminary assays on healthy controls (sub-optimal concentration 22.5 ng/ml). 
Notably, CVID patients have qualitatively and quantitatively different responses to 
stimulation with mitogens like PHA in vitro, notably decreased proliferative response 
(35). Thus, the sub-optimal dose of PHA in a CVID patient may differ from that of a 
healthy control, influencing the response to adjuvants. As the cytokine levels in cell 
culture supernatants from PHA stimulation in CVID patients differed in some degree 
from that of controls, a confounding effect on the response to adjuvants cannot be 
excluded. However, titrating the sub-optimal PHA response for both patients and 
controls to apply different doses of PHA to these two groups would cause a 
problematic methodological inconsistency.  Future studies should also examine the 
effect of other co-stimulants with relevance to CVID such as bacterial products and 
other cytokines. 
 
Statistical methods 
In line with the heterogeneous nature of CVID, most of the data analyzed in this thesis 
do not have a normal distribution and non-parametric methods of statistics have 
therefore been used. Non-parametric statistics are less influenced by outliers as found 
in heterogeneous data, but the use of ranks instead of absolute values and the impact 
of n analyzed on the p-value are a limitation. When reporting non-parametric data, it 
is customary to report median and a non-parametric measure of variability, such as 
25th to 75th percentiles. However, to improve readability in the highly condensed 
format required by medical journals, data are presented as mean ± SEM in some 
figures. 
  
4.2 DISCUSSION OF RESULTS 
4.2.1 Innate immune mechanisms in CVID 
 
Innate immunity can contribute to CVID pathogenetically through inept innate 
responses and subsequent inappropriate antigen-presentation, as suggested through 
immaturity of dendritic cells in CVID. The failure of the adaptive immune system in 
CVID can also make patients reliant on phylogenetically older and more primitive 
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immune responses, putting a strain on these and theoretically lead to either failure or 
compensatory enhancement of these mechanisms.   
MBL deficiency has been associated with respiratory infections in children 
although later studies have either have shown a weaker association than previously 
reported or no association at all (14;15;82-84). In an adult population low MBL levels 
do not seem to increase mortality or the occurrence of infectious disease, although 
conflicting data exist also here (16;85). However, low MBL levels have been 
associated with a poor prognosis in cystic fibrosis and also in immunocompromised 
hosts (86-88). The widespread existence of MBL deficiency suggest that MBL is of 
minor importance from an evolutionary point of view, and Turner et al. have proposed 
that pathology arising from MBL deficiency may require one or more co-existing 
immune deficits (89).  
The complement system, including the MBL pathway, has an important role in 
the innate immune response and dysregulation of this system may contribute to both 
susceptibility to infections and increased frequency of autoimmune and inflammatory 
manifestations in CVID. Indeed, Andersen et al. reported an association between 
structural mutations of the mbl2 gene and increased frequency of severe respiratory 
tract infections in CVID, and others have reported an association between low 
producing MBL alleles and earlier age of disease onset and autoimmunity in CVID 
(90;91).  
The study presented in paper I did not show increased prevalence of low MBL 
levels or lectin pathway deficiency in CVID patients compared to controls. This is 
consistent with the finding of Mullighan et al. in a study of 160 CVID patients in the 
UK (91). However, individuals with lectin pathway deficiency have a putative 
abnormal MBL synthesis and this may mask relevant differences in functional 
capacity of the lectin pathway and serum concentration of MBL between patients and 
controls with a normal synthesis of the protein (92;93). Thus, excluding subjects with 
lectin pathway deficiency, focusing on patients and controls with a normal MBL 
synthesis, functional capacity of the lectin pathway and MBL levels were significantly 
higher among CVID patients than controls. MBL has been considered a weak acute 
phase reactant, but although CRP levels were also raised among CVID patients, they 
did not correlate to MBL levels, suggesting at least partly different mechanisms of 
regulation.  Moreover, the patients in the present study had no obvious acute infection 
at the time of sampling and the stable MBL levels found during longitudinal testing 
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makes an elevation caused by intercurrent acute inflammation improbable. Elevated 
levels of MBL have also been reported in studies of chronic diseases such as cystic 
fibrosis, HIV infection and rheumatic heart disease (94-96). Little is known of factors 
regulating MBL beyond polymorphisms in the promoter regions and mutations in the 
MBL gene, and the reason for elevated levels of MBL and the possible clinical 
correlates in these chronic diseases remain largely unexplained.  
The major finding presented in paper I was a strong inverse correlation 
between MBL levels as well as functional capacity of the lectin pathway and the 
frequency of lower respiratory tract infection and bronchiectasis in the CVID group. 
In the before mentioned study by Andersen et al there was an association between 
structural mutations of the mbl2 gene and increased frequency of severe respiratory 
tract infections in CVID (90). In our study we extended these findings in several 
ways. While most studies, including the study by Andersen et al, have focused on 
MBL deficiency as defined by the presence of mutations in the MBL gene, we show a 
more continuous association between serum concentrations of MBL and lower 
respiratory tract infection and bronchiectasis. In fact, patients with MBL levels below 
500 ng/ml had increased frequency of lower respiratory tract infection and 
bronchiectasis, while patients with MBL levels above 4000 ng/ml had reduced 
frequency of these respiratory complications. Thus, it seems that while low MBL 
levels may predispose to lower respiratory tract infection and bronchiectasis in CVID, 
high MBL levels may protect against these complications in CVID. MBL can bind to 
a variety of bacteria and other microbes as well as their potentially toxic components, 
neutralizing them and/or opsonizing them by activating complement through the 
lectin pathway (97). It has furthermore been isolated in physiologically active levels 
in alveolar fluid from children with lower respiratory tract infection, suggesting that 
MBL is operating in the pulmonary microenvironment, giving some protection 
against the development of respiratory tract complications including bronchiectasis 
(98). Even though no data exist comparing MBL levels in alveolar fluid to MBL 
levels in the circulation, a mutated MBL gene would quite possibly lead to lower 
alveolar levels of MBL. Thus, MBL levels in CVID patients could contribute to 
airway complications, supporting, together with other studies, the principle proposed 
by Turner. Our finding of correlation between MBL levels and pulmonary 
complications in CVID has since been confirmed in another study (99). 
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There is a close correlation between the different MBL alleles and serum 
concentrations of MBL, but there is also a wide range of serum concentrations within 
each allele and a significant overlap of serum concentrations between these alleles 
(11-13). A mapping of MBL alleles could potentially help to identify MBL deficient 
subjects and was done in the study of Litzman showing increased frequency of 
respiratory complications to both genetically and biochemically assessed MBL-
deficiency (99). Importantly, genetic studies will not discriminate between normal 
MBL allele individuals with intermediate and high serum levels of MBL. Our study 
suggests that such discrimination may be clinically relevant as the various effects of 
MBL may be dose-dependent.  
Our findings indicating a protective effect of particularly high MBL levels 
may also suggest a therapeutic potential for MBL infusions as tested in small 
experimental studies (100). Furthermore, the identification of MBL in alveolar fluid 
in lower respiratory tract infection suggest the therapeutic potential of local, rather 
than systemic, administration of MBL in lower RTI, perhaps even in supra-
physiological doses. 
There are a few reports, mostly case studies, on complement deficiencies in 
CVID and the possible contribution of defects in the classical and alternative 
pathways has been uncertain (56;57). However, in our systematic study of the 
complement system in CVID we did not find any significant deficiencies of the 
classical or alternative pathways. We did, however, find signs of complement 
activation and this will be discussed in the next chapter. 
As evident by the vascular changes in acute inflammation, circulation and 
circulatory components are interwoven with human immune responses. The uPA 
system has an ambiguous role in infectious diseases where it may be involved in both 
harmful and beneficial inflammatory mechanisms during host response. In murine 
knock-out models loss of uPA is associated with low recruitment of T cells, 
granulocytes and macrophages to inflammatory tissue, and enhanced risk of bacterial 
infections (101-105). Furthermore, the uPA system is an activator of neutrophil 
granulocytes, enabling microbe killing by superoxide mechanisms, and uPA itself is 
shown to act as an endogenous antibiotic (8;106;107). As for uPA, uPAR has been 
shown to be involved in various inflammatory processes in murine knock-out models, 
most notably in the defence against bacterial infections (108;109). In bacterial 
infections, murine models support a beneficial role of uPAR through recruitment of 
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neutrophil granulocytes to inflamed tissue, and while this is generally considered  
protective it has been suggested to be harmful during meningitis (108-110). In HIV 
infections, high levels of suPAR are associated with a poor prognosis (111). The role 
of the uPA system in these innate immune responses is of particular interest in CVID 
where, as we have suggested through paper I, the compromised adaptive immune 
response potentially makes patients reliant on innate mechanisms of immune defence. 
Thus, the innate properties of an activated uPA system may be beneficial in acute and 
chronic bacterial infections in CVID. In the study presented in paper II we found 
increased circulating levels of suPAR and uPA, as well as increased monocyte 
expression of uPAR, suggesting an activation of the uPA system in CVID. We saw no 
correlation of suPAR to features associated with recurrent or chronic bacterial 
infections, making the potential link between suPAR and innate infectious responses 
uncertain.  
Raised levels of MBL and the activation of the uPA system may both 
contribute to increased innate protection in patients with a failing adaptive immune 
response. Although much is unknown about the specific regulation of both MBL and 
the uPA-system, the potential consequence of their up-regulation makes it tempting to 
consider their up-regulation as representing some form of compensatory mechanism.  
 
4.2.2 Inflammatory mechanisms in CVID  
The inflammatory manifestations of CVID are clinically heterogeneous. All patients 
are subject to inflammation during intercurrent infections or autoimmune disease but 
some patients display immune activation even when no active infection or 
autoimmune disease has been detected suggesting an underlying inflammatory 
phenotype (42;45;55). The constitutive nature of this inflammation in CVID is 
supported by the contrast to patients with XLA, which despite their 
hypogammaglobulinemia and intercurrent infections fail to exhibit these 
inflammatory manifestations. In investigating these features of CVID, the exclusion 
of patients with current infections or autoimmune disease requiring anti-inflammatory 
treatment, like active ITP or arthritis, is of importance. The manifestations of this 
inflammatory phenotype are persistent and thus chronic, but of a different nature than 
chronic inflammation seen in a patient with e.g. a chronically infected pulmonary 
focus. We have used the term chronic inflammation in vivo to describe this phenotype 
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and it shares some characteristics with the para-inflammation suggested by 
Medzhitov; there is no classic chronic inflammatory focus but rather a systemic and 
persistent activation of the immune system (5). The characteristics of this 
inflammatory phenotype will be discussed here as well as in the next chapter of 
regulation of inflammation in CVID. 
Immunological characteristics of this inflammatory phenotype includes 
enhanced levels of markers consistent with persistent immune activation, in particular 
markers associated with monocyte activation (43;45;55). Furthermore, several studies 
have pointed towards a TH1 favored immune activation in CVID, based on increased 
serum levels of IL-12, as well as enhancement of the IL-12/IFN- cytokine loop in 
monocytes and T cells (47;49;50). CVID is also characterized by relatively high 
levels of CCR7- + and CD4 CD45RA- T cells in peripheral blood, corresponding to a 
shift from a naïve lymph-node homing phenotype to an effector/memory tissue-
homing phenotype of T cells (62;64-66). Clinically, these patients are characterized 
by lymphoid hyperplasia, typically splenomegaly, and high frequency of autoimmune 
disease, in particular ITP. Thus, identifying patients with chronic inflammation in vivo 
we have classified patients based on serum levels of neopterin and presence of 
splenomegaly into the CVIDHyper group as has been accounted for previously. I will 
now consider the contribution of factors studied in this thesis on this inflammatory 
phenotype. 
 
Contribution of the complement system 
The complement system plays a central role in the host defence against microbes but 
enhanced complement activation may also induce tissue damage and inflammation. 
Accordingly, a dysregulated complement system has been associated both with 
increased susceptibility to infections and autoimmune diseases (9;10). In CVID, low 
producing MBL alleles has been associated with autoimmunity but in paper I we 
found no such association between low serum levels of MBL and autoimmunity 
within the CVID group (91). Interestingly, CVID patients had increased functional 
capacity in both the classical and alternative pathways compared to controls, with 
increased levels of complement split products (i.e., C3a, C4a and C5a).This 
complement activation, and in particular the release of inflammatory mediators such 
as C5a, could potentially contribute to inflammatory and autoimmune manifestations 
characterizing CVID. Indeed, we found an association between high levels of factor B 
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and splenomegaly, between high levels of factor B, C1q and C3 and granulomatous 
disease, and between high levels of C3a and idiopathic thrombocytopenia. These 
findings suggest that enhanced complement activation is another inflammatory 
characteristic of CVID patients.    
 
Contribution of the uPA system 
Enhanced uPA activation has been seen in inflammatory disorders such as rheumatoid 
arthritis, atherosclerosis and asthma (112-114). In humans, high levels of components 
of the uPA system, which include uPA, uPAR and suPAR, have been found in 
malignant, inflammatory and infectious diseases (115-119). In paper II we show 
increased plasma levels of suPAR in all CVID patients, with particularly high levels 
in subgroups with an inflammatory phenotype characterised by thrombocytopenia and 
splenomegaly. Levels of uPA followed the same pattern with significant enhancement 
in patients with splenomegaly and thrombocytopenia. Within the CVID population 
levels of both suPAR and uPA correlated to neopterin, which have been shown to 
covariate with suPAR in other studies(120;121). Moreover, monocytes from CVID 
patients had enhanced cellular expression of uPAR, further supporting a link between 
increased activity in the uPA system and monocyte activation in these patients.  
Indeed, activated monocytes are a probable candidate for suPAR production in CVID, 
with a possible contribution of enhanced uPA-mediated proteolytic activity in 
subgroups of patients (122;123). While our study found a strong association to 
monocyte activation we also found a down-regulation of uPAR in T cells from CVID 
patients. Lymphocytes are generally a poor reservoir for uPAR even if increased 
expression is seen on activation of T cells, and the observed down-regulation might 
reflect the phenotypic shift of T cells previously reported in CVID, including an 
altered CD4/CD8 cell ratio and low levels of naïve CD4+ cells (124;125). 
Nevertheless, in vitro studies and studies in animal models suggest a role for uPAR in 
T-cell activation promoting cell proliferation and release of cytokines, including T-
cell derived B-cell growth factors (126). The decreased expression of uPAR on T cells 
from these patients may potentially contribute to impaired T-cell function seen in 
subgroups of CVID patients, but the findings in paper II primarily supports a role for 
the uPA system in monocyte activation in CVID. 
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Contribution of the fractalkine system 
The high expression of chemokines is a characteristic feature of inflammation, and 
importantly their chemotactic effects are supplemented by their inflammatory effects, 
meaning chemokines will both direct and activate cells. The chemokine fractalkine, 
CX3CL1, and its receptor, CX3CR1, are associated with the pathogenesis of several 
inflammatory disorders such as glomerulonephritis, rheumatoid arthritis, systemic 
lupus erythematosus, atherosclerosis and HIV infection (127-135). We have 
previously observed that the gene for CX3CR1 is up-regulated in T cells in a group of 
CVID patients characterized by low T-cell proliferation in vitro, and in paper III we 
investigated more properties of the fractalkine system in CVID (64). Elevated levels 
of CX3CL1 in serum have been observed in various inflammatory conditions, and it 
has been suggested to reflect enhanced localized release from an inflamed and 
activated endothelium (130;131;133;134;136). We found raised levels of CX3CL1 in 
all CVID patients, while there was no elevation of vWF, a known marker of 
endothelial activity. The differential secretion of CX3CL1 and vWF from 
endothelium is documented in vitro, where CX3CL1 expression is induced by IFN-, 
while expression of vWF is attenuated (137-139). Notably, increased IFN- activation 
has been reported in CVID suggesting that a similar mechanism of selective activation 
of CX3CL1 may occur in CVID in vivo. Alternatively, CX3CL1 may be produced by 
extravascular cells as the chemokine is constitutively expressed in various tissues, 
among them skeletal muscle, colon and lung, and can be induced in several cell types 
including smooth muscle cells, dendritic cells and intestinal epithelium (127;140-
142).  
We confirmed our previous microarray experiments through showing 
increased CX3CR1 expression on T cells from CVID patients by means of flow 
cytometry and PCR, and interestingly, the receptor was most markedly expressed on 
T cells from the CVIDHyper subgroup. Normally, the receptor CX3CR1 is expressed on 
cells from the hematopoetic lineage, most notably in monocytes and cytotoxic 
lymphocytes such as NK-cells,  T cells and CD8+ effector cells, but also to some 
extent in CD4+CD45RA- effector memory cells (129;143). While we did find 
relatively high levels of  both CD8+ cells and CD4+CD45RA- cells in the CVID 
population, this could not account for the increased expression of CX3CR1 in the 
CVID +Hyper group as this was observed in CD4  and CD8+ cells, as well as CD45RA+ 
and CD45RA- cells. Thus, the increased expression of CX3CR1 in T cells from 
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CVIDHyper patients does not merely reflect a phenotypic shift of T cells in peripheral 
blood of these patients. Importantly, it seems that CX3CL1 induce inflammatory 
responses in PBMC from CVIDHyper patients, suggesting that the increased expression 
of CX3CR1 in cells from these patients may affect their functional responses. Thus, 
increased serum levels of CX3CL1 as well as enhanced T-cell expression of CX3CR1 
in CVIDHyper patients may contribute to the inflammatory phenotype seen in these 
patients. In contrast, while CX3CR1 is involved in monocyte survival and function, 
we found no differential regulation of the receptor in monocytes from CVID patients 
(144). 
Previous studies have shown pro-inflammatory effects of CX3CL1 associated 
with a TH1 response (145;146). As CX3CR1 has been localized in polarized TH1 cells 
and CX3CL1 expression in endothelial cells is induced by CD40L and IFN-, the 
CX3CL1/CX3CR1 system has been suggested to be part of an amplification circuit of 
a TH1 response (146;147). The upregulation of the CX3CL1/CX3CR1 system 
demonstrated in paper III may therefore also reflect an amplification and polarization 
of the previously suggested TH1 skewed response in CVID (47).  
We have previously shown extensive T-cell abnormalities in CVID, ranging 
from increased cytotoxic activity to alteration of adhesion processes and our findings 
presented in paper III supports the role of T-cell pathology in CVID (64;148-150).  
 
Contribution of CCL19, CCL21 and CCR7 
While most chemokines have been linked to inflammatory processes in peripheral 
tissue, the homeostatic chemokines CCL19 and CCL21 and their corresponding 
receptor CCR7 have traditionally been associated with development and maintenance 
of secondary lymphoid organs, as well as the entry of lymphocytes and dendritic cells 
to secondary lymphoid tissue (151;152). Recently, however, reports have pointed to a 
broader role for these homeostatic chemokines, including modulation of inflammatory 
and anti-inflammatory responses in peripheral tissue. An imbalanced regulation of 
CCL19 and CCL21has been suggested to be involved in the pathogenesis of various 
inflammatory disorders including rheumatoid arthritis, inflammatory bowel diseases 
and atherosclerosis (153-157). In paper IV we extend these findings by showing 
raised serum levels of CCL19 and CCL21 in CVID patients as compared with 
controls. While CCL19 and CCL21 are mainly expressed in lymphoid tissue, 
circulating levels of CCL19 and CCL21 possibly also reflect expression in peripheral 
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inflamed tissue. CVID patients are prone to both recurrent and chronic bacterial 
infections, providing inflammatory foci that might contribute to levels of CCL19 and 
CCL21. Bronchiectasis are frequently associated with bacterial infection in CVID and 
while both patients with and without bronchiectasis had raised levels of CCL19 
compared to controls this was most notable in patients with this complication. It is 
therefore possible that the infections seen in CVID patients with bronchiectasis 
contribute to the high levels of CCL19 seen in this subgroup of patients. The presence 
of splenomegaly, contributing to increased lymphoid mass in the CVIDHyper group, 
was not correlated to serum levels of CCL19 and CCL21. Furthermore, there was a 
similar expression of CCL19 in spleen tissue from both controls and CVID patients, 
while CCL21 was variably down-regulated in spleens from patients, making spleen a 
less likely source for the elevation of these chemokines in patients. Monocytes from 
the CVIDHyper group tended towards enhanced expression of CCL19, and a possible 
contribution from monocytes to serum levels of CCL19 in this subgroup cannot be 
excluded. Thus, even if the raised serum levels of CCL19 might be related to both 
inflammatory cells associated with bronchiectasis and monocyte activation, the serum 
levels of CCL19 and CCL 21 seem elevated independently of features of chronic 
inflammation in CVID.  
As commented upon, we and others have previously shown the down-
regulation of CCR7 on T cells in groups of CVID patients (64-66). In paper IV we 
supplement these findings by showing particularly low proportions of CD3+ +CCR7   in 
the CVIDHyper group, suggesting that this characteristic is another inflammatory 
feature of this subgroup. Interestingly, while expression of CCR7 is markedly affected 
in the CVIDHyper group, the levels of CCL19 and CCL21 are not and moreover, there 
is no correlation between levels of CCL19 and CCL21 and T-cell expression of 
CCR7.  Thus, even if CCL19 has been shown to modify cellular CCR7 expression, 
our study suggests that expression of CCR7 on circulating T cells is regulated at least 
partly independent of its ligands in CVID (158).  
Stimulation of CCR7+ cells with CCL19 and CCL21 in various settings has 
shown important modulation of cell responses by these chemokines, but in contrast to 
the modulatory effects of CCL19 and CCL21 seen in PBMC from healthy controls, 
cells from CVID patients gave no significant response to CCL19 and CCL21 
stimulation (155;159;160). The results presented in paper IV supports a constitutive 
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enhancement of CCL19 and CCL21 in CVID, while CCR7 seems related to 
inflammatory features. 
 
Concerning lymphoid hyperplasia and granulomatous disease 
In paper IV, we present histological characteristics of splenomegaly in nine CVID 
patients, and notably splenomegaly in CVID is histologically heterogeneous. Some 
patients have markedly increased white pulp consistent with an increase of lymphoid 
cells in the spleen while others have normal or even small white pulp. In paper III-IV 
we demonstrate increased levels of chemokines normally expressed in secondary 
lymphoid tissue; CX3CL1, CCL19 and CCL21 but only CX3CL1 was associated with 
lymphoid hyperplasia. Furthermore, T cells from the CVIDHyper group showed 
significantly enhanced chemotactic and adhesive properties to stimulation with 
CX3CL1. As CX3CL1 is strongly expressed in high endothelial venules of reactive 
hyperplastic lymph nodes it is tempting to suggest that the enhanced CX3CR1 
expression on T cells might be involved in an abnormal pattern of lymphocyte 
migration in CVID (161).  
Serum levels of CCL19 and CCL21 were expressed independently of 
lymphoid hyperplasia but their receptor, CCR7, was not. In contrast to the diminished 
CCR7 expression on circulating T cells in CVID, spleens from CVID patients showed 
a similar expression of CCR7 as compared to controls, suggesting the down-
regulation of CCR7 in CVID does not affect all lymphoid compartments.  
 
4.2.3 Regulatory immune mechanisms in CVID 
 
Regulatory immune mechanisms are closely linked to autoimmunity. The apparent 
paradox of increased frequency of both infections and autoimmunity in CVID defy a 
view of infections and autoimmunity as examples of merely attenuated and 
exaggerated immune responses, respectively. Several mechanisms have been 
suggested to cause autoimmunity in CVID, including defective clearing of external 
antigens, genetic predisposition, immune dysregulation and breakdown in 
mechanisms of tolerance (162). However, the growing understanding of tolerance to 
innocuous antigens as an active process requiring presence and function of specially 
designated cells, mimicking the response to pathological antigens, has clarified a 
possible link between autoimmunity and infections in CVID (24).  
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The concept of tolerance was introduced previously, and while defective 
central tolerance, e.g. failure of apoptosis of autoreactive lymphocytes, might 
contribute to autoimmunity in CVID this has been scarcely commented upon. 
Peripheral tolerance can be mediated by several subgroups of T cells, and in particular 
the role of TReg in conditions such as transplant rejection reactions, cancer, 
autoimmunity, and chronic infectious diseases has been a subject of active 
investigation (163-167). In paper V we investigated whether CVID, with its high 
frequency of autoimmunity and signs of chronic inflammation, might be characterized 
by T  abnormalities. Reg
We show that CVID patients have decreased proportions of TReg as compared 
to controls. The decreased proportions of these CD4+ High +CD25 FoxP3  cells in CVID 
is further supported by low expression of FoxP3 mRNA in CD3+ cells in the same 
patients. Interestingly, we find the lowest proportions of TReg in CVID patients with 
splenomegaly and a negative correlation between levels of neopterin and proportions 
of T . Thus, we find a link between decrease of TReg Reg and CVID patients 
characterized by chronic inflammation in vivo. This link raises interesting questions 
regarding both homeostasis and function of TReg. The immediate reason for the low 
numbers of TReg in CVID patients with splenomegaly is unclear; while low numbers 
of circulatory CD4+CD25High cells have been observed in some other diseases, even 
without splenomegaly, this is less well documented for CD4+ HighCD25 FoxP3+ cells 
(164;168;169). The homeostasis of TReg is  controlled by several factors, among them 
the differentiation of TReg in the thymus, induction and/or expansion of TReg in the 
periphery, half-life of T  in the circulation and possible redistribution of TReg Reg to 
extra-vascular tissue (170). We can only speculate which factors contribute to our 
finding but one possibility is that the observed maturation defects of effector T cells in 
CVID also applies to the development of T . The link between low numbers of TReg Reg 
and chronic inflammation can also be seen from a more functional perspective. In 
acute inflammation it has been suggested that feed-back mechanisms cause a relative 
decrease in TReg early in the process to allow for an effective immune response, 
followed by an increase in TReg to reduce the response when the antigen is cleared 
(21). In chronic inflammation, low numbers of TReg could reflect dysfunctional 
feedback mechanisms, failed clearance of an offending antigen or a more constitutive 
defect of T  as seen in the IPEX syndrome (24).  Reg
TReg execute their suppressive role through different mechanisms, including 
 54
the secretion of IL-10 and TGF-. We have previously reported decreased secretion of 
IL-10 in T-cell cultures from CVID patients, and interestingly we found a correlation 
between secreted IL-10 levels in T-cell cultures and TReg numbers in CVID, 
supporting the link between IL-10 and TReg (70). Recent studies have further 
suggested that a balanced interaction between CCL19, CCL21 and CCR7 is necessary 
not only for the optimal initiation of protective immunity against various 
microorganisms, but also for the induction of peripheral tolerance and the regulation 
of the immune response by TReg (151;171;172). It is tempting to hypothesize that the 
inability of CCL19 and CCL21 to induce the release of several important 
immunoregulatory cytokines in PBMC from CVID patients, as presented in paper IV, 
could be involved in the defective regulation of the immune response in CVID. 
CCL19/CCL21 deficiency has been associated with both a delayed and exaggerated 
response to antigens in a murine model, a picture mirroring the increased frequency of 
infections and autoimmunity seen in CVID (171).  
The results presented in paper V show a role for TReg in CVID pathology, in 
particular in patients with chronic inflammation in vivo, suggesting that this 
immunodeficiency is characterised not only by inept adaptive responses and chronic 
inflammation, but also a profound dysregulation of cellular responses. The potential 
of T  associated anti-inflammatory therapy might thus also apply to CVID. Reg
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 55
5. CONCLUSION  
 
CVID represents an immunodeficiency enabling us to understand not only the 
characteristics of a defect immune system but also important aspects of the functional 
immune system. In the studies of this thesis we present novel insights into innate, 
inflammatory and regulatory immunological features of CVID that contribute to the 
multi-faceted pathology of this disease. Notably, we suggest the possible detrimental 
contribution of MBL deficiency to respiratory complications in patients already 
deficient of an adequate adaptive immune response. We show an inappropriate 
activation of the suPAR and fractalkine systems associated with a subgroup of CVID 
patients characterised by an inflammatory phenotype. We find constitutively 
enhanced levels of the chemokines CCL19 and CCL21 possibly contributing to the 
immune dysregulation in CVID. Last, we demonstrate decreased proportions of TReg 
in CVID patients, particularly in those with signs of an inflammatory phenotype, 
further suggesting a profound perturbation of the immune system in CVID.  
The mainstay treatment of CVID today is substitution of IgG through 
intravenous or subcutaneous administration. This leads to drastic improvement of 
symptoms in many patients but some still suffer from particularly respiratory 
infections, while others present with autoimmune disease not conveniently treated in 
immunodeficient patients. The studies presented in this thesis add to the knowledge 
that may be needed to address these clinical problems in CVID, while also shedding 
light on processes of importance in other immunodeficiencies and inflammatory 
disease.    
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